An Open-Label Study of Herbal Topical Medication (Psirelax) For Patients With Chronic Plaque Psoriasis

  • Shiri J. Clalit Health Services
  • Cicurel A. Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva
  • Cohen A. D. Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva

Abstract

Psirelax is an herbal topical medication indicated for the treatment of patients with psoriasis. Its efficacy was determined in an open-label study in 22 patients (15 men, 7 women) with a mean age of 48.9±11.8 years suffering from chronic plaque psoriasis. The patients were treated by application of Psirelax twice a day for a period of 4 weeks. Clinical assessment was performed using the Psoriasis Area and Severity Index (PASI) and the Beer-Sheva Psoriasis Severity Score (BPSS). The results shows that Psirelax was well tolerated and there no local or systemic side effects. There was 59% reduction in PASI, from a mean of 5.9 ± 4.0 before treatment to 2.4 ± 2.4 after treatment (p<0.001). In 8 patients (36%) PASI decreased in more than 75% (PASI75). In 16 patients (73%) PASI decreased in more than 50% (PASI50). Application of Psirelax was associated with a decrease in disease severity, as assessed by the patients and physicians. It is concluded that Psirelax treatment was well tolerated in patients with chronic plaque psoriasis.
Published
2012-06-22
Section
ARTICLES